SR T100

Drug Profile

SR T100

Alternative Names: SR-T100; SR-T100 gel

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator G&E Herbal Biotechnology
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Condylomata acuminata
  • Phase 0 Vulvar intraepithelial neoplasia

Most Recent Events

  • 06 Dec 2017 G&E Herbal Biotechnology plans a phase II trial for Warts in Taiwan, in June 2018 (NCT01796795)
  • 12 Sep 2017 SR T100 is still in phase II trials for Condylomata acuminata in Taiwan (Topical) (NCT01796821)
  • 31 Jul 2017 G&E Herbal Biotechnology withdraws a planned phase II trial for Common warts in Taiwan (Topical) due to budget issues (NCT01796795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top